| Title | Rethinking screening for breast cancer and prostate cancer. | | Author(s) | Esserman L, Shieh Y, Thompson I | | Institution | Department of Surgery and Radiology, University of California, San Francisco, San Francisco, CA 94115, USA. laura.esserman@ucsfmedctr.org | | Source | JAMA 2009 Oct 21; 302(15):1685-92. | | MeSH | Breast Neoplasms
Cost of Illness
Early Detection of Cancer
Female
Forecasting
Humans
Male
Mammography
Mass Screening
Prostate-Specific Antigen
Prostatic Neoplasms
Risk Assessment
Tumor Markers, Biological
United States
| | Abstract | After 20 years of screening for breast and prostate cancer, several observations can be made. First, the incidence of these cancers increased after the introduction of screening but has never returned to prescreening levels. Second, the increase in the relative fraction of early stage cancers has increased. Third, the incidence of regional cancers has not decreased at a commensurate rate. One possible explanation is that screening may be increasing the burden of low-risk cancers without significantly reducing the burden of more aggressively growing cancers and therefore not resulting in the anticipated reduction in cancer mortality. To reduce morbidity and mortality from prostate cancer and breast cancer, new approaches for screening, early detection, and prevention for both diseases should be considered. | | Language | eng | | Pub Type(s) | Journal Article
Research Support, N.I.H., Extramural
| | PubMed ID | 19843904 |
|
